Literature DB >> 25546792

Human immunoglobulin G for experimental treatment of Duchenne muscular dystrophy.

J Zschüntzsch1, P Jouvenal, Y Zhang, F Klinker, M Tiburcy, D Malzahn, D Liebetanz, H Brinkmeier, J Schmidt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25546792      PMCID： PMC4285521          DOI： 10.1111/cei.12541

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  5 in total

Review 1.  Emerging drugs for Duchenne muscular dystrophy.

Authors:  Vinod Malik; Louise R Rodino-Klapac; Jerry R Mendell
Journal:  Expert Opin Emerg Drugs       Date:  2012-06       Impact factor: 4.191

2.  Motor performance of young dystrophic mdx mice treated with long-circulating prednisolone liposomes.

Authors:  Charlotte Weller; Jana Zschüntzsch; Gregor Makosch; Josbert M Metselaar; Florian Klinker; Lars Klinge; David Liebetanz; Jens Schmidt
Journal:  J Neurosci Res       Date:  2012-01-18       Impact factor: 4.164

Review 3.  Pathophysiology of duchenne muscular dystrophy: current hypotheses.

Authors:  Nicolas Deconinck; Bernard Dan
Journal:  Pediatr Neurol       Date:  2007-01       Impact factor: 3.372

Review 4.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management.

Authors:  Katharine Bushby; Richard Finkel; David J Birnkrant; Laura E Case; Paula R Clemens; Linda Cripe; Ajay Kaul; Kathi Kinnett; Craig McDonald; Shree Pandya; James Poysky; Frederic Shapiro; Jean Tomezsko; Carolyn Constantin
Journal:  Lancet Neurol       Date:  2009-11-27       Impact factor: 44.182

Review 5.  Muscular dystrophy into the new millennium.

Authors:  Alan E H Emery
Journal:  Neuromuscul Disord       Date:  2002-05       Impact factor: 4.296
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.